Vivo BIO Tech Ltd.

NSE: VIVOBIOT · Biotechnology · sector

₹12.89NSE close 2026-10-26

Key numbers

Market cap₹29 cr

Price₹12.89

52w high / low₹21 / ₹13

P/E3.6xSector median 40.2x

P/B0.3xSector median 1.4x

Book value₹42.0

Dividend yield–Sector median 2.11%

ROE-3.3%Sector median -0.0%

ROCE5.8%Sector median 3.3%

OPM37.0%Sector median 31.3%

Debt / equity0.72xSector median 0.01x

EV/EBITDA4.6xSector median 34.1x

Interest cover1.7x

Current ratio0.94x

Sales growth 3y+1.1%Sector median -26.4%

Profit growth 3y–Sector median -43.0%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 6 companies in Biotechnology (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹67 cr (FY26): borrowings are higher by ₹66 cr.
Operating profit covered interest 1.7x in the last 12 months.
Net loss in 1 of the last 6 quarters.
No dividend in the last 5 financial years.
Price ₹12.89 on 2026-10-26: -38.4% from the 52-week high, +0.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹49.92 · low ₹12.89

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	12	13	13	14	14	14
EBITDA	5	5	5	5	4	5
OPM %	40.8%	43.9%	41.3%	40.6%	31.3%	35.4%
Other income	0	0	0	0	0	0
Net profit	1	1	1	1	-5	0
EPS (₹)	0.69	0.74	0.45	0.56	2.52	0.08
Revenue YoY					+15.5%	+14.1%
Profit YoY					-586.8%	-85.8%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	51	52	45	47	53	55
EBITDA	16	21	21	21	21	20
Net profit	2	3	3	7	-2	-3
EPS (₹)	1.56	1.77	1.69	4.76	0.82	3.61
Revenue growth		+0.4%	-13.1%	+4.0%	+14.3%	–
Profit growth		+19.5%	-4.2%	+188.9%	-123.5%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+1.1%	–	–
Net profit	–	–	–
EPS	-22.6%	–	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	78	93
Borrowings	54	67
Cash & equivalents	1	1
Total assets	143	178
Fixed assets	64	72
Capital work in progress	13	5
Investments	0	22
Receivables	11	12
Inventory	8	8
Payables	0	2

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	12	35
Cash from investing	-16	-59
Cash from financing	4	25
Capex	22	37
Free cash flow	-10	-3

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	9.3%	-1.8%
ROCE %	12.4%	6.6%
Debtor days	88	80
Inventory days	491	366
Payable days	0	88
Cash conversion cycle (days)	579	358
Working capital days	110	-12

Peers in Biotechnology

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
ANTHEM	₹46,324 cr	80.2x	15.2x	18.9%	25.5%	38.4%	–	–
ADVENZYMES	₹2,823 cr	17.0x	1.7x	10.9%	14.1%	31.3%	+11.3%	2.11%
CCME	₹43 cr	58.0x	1.1x	-3.5%	-2.1%	–	–	–
VIVOBIOT	₹29 cr	3.6x	0.3x	-3.3%	5.8%	37.0%	+1.1%	–
SHREEGANES	₹18 cr	22.5x	0.3x	-0.6%	-0.6%	-35.1%	-57.0%	–
GVBL	₹12 cr	329.9x	3.1x	0.5%	0.8%	15.6%	-53.8%	–

All 6 companies in Biotechnology →

Dividends & corporate actions

Ex-date	Action	Detail
2002-08-08	Dividend	NIL Dividend

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Biotechnology
Sub-industry	Biotechnology
Symbol	VIVOBIOT
BSE code	511509
ISIN	INE380K01017
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.